Sign In
Buy TAK
$17.09
-0.160 (-0.93%)
At Close: Jul 31, 2026
Best Income Stocks to Buy for April 30th
09:05am, Wednesday, 30'th Apr 2025
SKM, TAK and SONY made it to the Zacks Rank #1 (Strong Buy) income stocks list on April 30, 2025.
Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM Education
08:05am, Wednesday, 30'th Apr 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda has awarded grants to seven nonprofits that share its commitment to creating better health for people and a brighter future for the world.
New Strong Buy Stocks for April 30th
05:50am, Wednesday, 30'th Apr 2025
DB, SPOT, SONY, CIVB and TAK have been added to the Zacks Rank #1 (Strong Buy) List on April 30, 2025.
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
10:45am, Monday, 21'st Apr 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
TAK vs. DSNKY: Which Stock Is the Better Value Option?
12:46pm, Wednesday, 16'th Apr 2025
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3
07:15am, Tuesday, 08'th Apr 2025
LUND, SWEDEN / ACCESS Newswire / April 8, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-clas
Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?
10:46am, Friday, 04'th Apr 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns
02:27pm, Tuesday, 01'st Apr 2025
Takeda's AI-powered "returning to growth" program has improved profit margins, leading to upgraded FY2024 guidance and a JPY100 billion share buyback program. Takeda's Rusfertide and Protagonist's Ico
TAK vs. DSNKY: Which Stock Should Value Investors Buy Now?
12:45pm, Monday, 31'st Mar 2025
Investors interested in Medical - Drugs stocks are likely familiar with Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?
10:40am, Wednesday, 19'th Mar 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
TAK or DSNKY: Which Is the Better Value Stock Right Now?
12:41pm, Friday, 14'th Mar 2025
Investors interested in Medical - Drugs stocks are likely familiar with Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds
03:45am, Thursday, 13'th Mar 2025
Japan-based Takeda Pharmaceutical, which has its ADR listed on the NYSE, gets a buy rating today, agreeing with the analyst consensus. Besides a diverse drug portfolio across multiple segments, they h
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
10:46am, Monday, 03'rd Mar 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline resu
TAKHZYRO Solution for Injection in 2 mL Pre-Filled Pen is Now Approved to Facilitate Subcutaneous Administration in Adolescent (Aged 12 Years and Above) and Adult Patients with HAE.1 The Pre-Filled Pe
